Publications 2021

Guldvik IJ, Ekseth L, Kishan AU, Stensvold A, Inderberg EM, Lilleby W (2021)
Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer
J Pers Med, 11 (7)
DOI 10.3390/jpm11070605, PubMed 34206815

Ramberg H, Richardsen E, de Souza GA, Rakaee M, Stensland ME, Braadland PR, Nygård S, Ögren O, Guldvik IJ, Berge V, Svindland A, Taskén KA, Andersen S (2021)
Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer
Carcinogenesis, 42 (5), 685-693
DOI 10.1093/carcin/bgab015, PubMed 33609362

Publications 2020

Guldvik I, Askheim OP (2020)
Constructing user participation for disabled people-the Norwegian context
Disabil. Soc.
DOI 10.1080/09687599.2020.1867070

Guldvik IJ, Zuber V, Braadland PR, Grytli HH, Ramberg H, Lilleby W, Thiede B, Zucknick M, Saatcioglu F, Gislefoss R, Kvåle R, George A, Grönberg H, Wiklund F, Neal DE, Gnanapragasam VJ, Taskén KA, Mills IG (2020)
Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification
Eur Urol Open Sci, 21, 51-60
DOI 10.1016/j.euros.2020.08.007, PubMed 34337468

Publications 2019

Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, Bjartell A, Taskén KA (2019)
The β₂-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
Mol Cancer Res, 17 (11), 2154-2168
DOI 10.1158/1541-7786.MCR-18-0605, PubMed 31395667

Connell SP, Hanna M, McCarthy F, Hurst R, Webb M, Curley H, Walker H, Mills R, Ball RY, Sanda MG, Pellegrini KL, Patil D, Perry AS, Schalken J, Pandha H, Whitaker H, Dennis N, Stuttle C, Mills IG, Guldvik I, Movember GAP1 Urine Biomarker Consortium, Parker C, Brewer DS, Cooper CS, Clark J (2019)
A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients
BJU Int, 124 (4), 609-620
DOI 10.1111/bju.14811, PubMed 31106513

Webb M, Manley K, Olivan M, Guldvik I, Palczynska M, Hurst R, Connell SP, Mills IG, Brewer DS, Mills R, Cooper CS, Clark J (2019)
Methodology for the at-home collection of urine samples for prostate cancer detection
Biotechniques, 68 (2), 65-71
DOI 10.2144/btn-2019-0092, PubMed 31779479

Publications 2018

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2018)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 118 (6), e11
DOI 10.1038/bjc.2017.470, PubMed 29462127

Publications 2017

Askheim OP, Christensen K, Fluge S, Guldvik I (2017)
User participation in the Norwegian Welfare Context: an Analysis of Policy Discourses
J. Soc. Policy, 46 (3), 583-601
DOI 10.1017/S0047279416000817

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2017)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 117 (11), 1656-1664
DOI 10.1038/bjc.2017.346, PubMed 28972967

Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, Erho N, Bloch K, Davicioni E, Derua R, Waelkens E, Mohler JL, Clarke N, Swinnen JV, Keun HC, Rekvig OP, Mills IG (2017)
Lipid degradation promotes prostate cancer cell survival
Oncotarget, 8 (24), 38264-38275
DOI 10.18632/oncotarget.16123, PubMed 28415728

Publications 2015

Bollineni RC, Guldvik IJ, Grönberg H, Wiklund F, Mills IG, Thiede B (2015)
A differential protein solubility approach for the depletion of highly abundant proteins in plasma using ammonium sulfate
Analyst, 140 (24), 8109-17
DOI 10.1039/c5an01560j, PubMed 26541119

Publications 2014

Itkonen HM, Engedal N, Babaie E, Luhr M, Guldvik IJ, Minner S, Hohloch J, Tsourlakis MC, Schlomm T, Mills IG (2014)
UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation
Oncogene, 34 (28), 3744-50
DOI 10.1038/onc.2014.307, PubMed 25241896

Publications 2013

Engedal N, Torgersen ML, Guldvik IJ, Barfeld SJ, Bakula D, Sætre F, Hagen LK, Patterson JB, Proikas-Cezanne T, Seglen PO, Simonsen A, Mills IG (2013)
Modulation of intracellular calcium homeostasis blocks autophagosome formation
Autophagy, 9 (10), 1475-90
DOI 10.4161/auto.25900, PubMed 23970164

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
Int J Cancer, 133 (6), 1497-506
DOI 10.1002/ijc.28158, PubMed 23494569

Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, Svindland A, Schlomm T, Mills IG (2013)
O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells
Cancer Res, 73 (16), 5277-87
DOI 10.1158/0008-5472.CAN-13-0549, PubMed 23720054

Publications 2011

Risberg K, Guldvik IJ, Palchaudhuri R, Xi Y, Ju J, Fodstad O, Hergenrother PJ, Andersson Y (2011)
Triphenylmethyl derivatives enhances the anticancer effect of immunotoxins
J Immunother, 34 (5), 438-47
DOI 10.1097/CJI.0b013e31821e00ae, PubMed 21577141

Publications 2008

Perander M, Aberg E, Johansen B, Dreyer B, Guldvik IJ, Outzen H, Keyse SM, Seternes OM (2008)
The Ser(186) phospho-acceptor site within ERK4 is essential for its ability to interact with and activate PRAK/MK5
Biochem J, 411 (3), 613-22
DOI 10.1042/BJ20071369, PubMed 18248330